Andrea De Salvo

Dr. Andrea De Salvo

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2023 in JCI Insight
Verified
Journal Article
Open access
PDF file
MVMarina Vivarelli
Marina Vivarelli
MCManuela Colucci
Manuela Colucci
MAMattia Algeri
Mattia Algeri
FZFederica Zotta
Federica Zotta
FEFrancesco Emma
Francesco Emma
PRPiero Ruggenenti
Piero Ruggenenti
BACKGROUND: Severe forms of idiopathic nephrotic syndrome (INS) require prolonged immunosuppressive therapies and repeated courses of high-dose glucocorticoids. Mesenchymal stromal cells (MSCs) have promising immunomodulatory properties that may be employed therapeutically to reduce patient exposure to medications and their side effects. METHODS: We performed a phase I open-label trial assessing safety and feasibility of autologous bone marrow–derived MSCs (BM-MSCs) in children and young adults with severe forms of steroid-dependent nephrotic syndrome. Following autologous BM-MSC preparation and infusion, oral immunosuppression was tapered. Safety, efficacy, and immunomodulatory effects in vivo were monitored for 12 months. RESULTS: Sixteen patients (10 children, 6 adults) were treated. Adverse events were limited and not related to BM-MSC infusions. All patients relapsed during follow-up, but in the 10 treated children, time to first relapse was delayed ( P = 0.02) and number of relapses was reduced ( P = 0.002) after BM-MSC infusion, compared with the previous 12 months. Cumulative prednisone dose was also reduced at 12 months compared with baseline ( P < 0.05). No treatment benefit was observed in adults. In children, despite tapering of immunosuppression, clinical benefit was mirrored by a significant reduction in total CD19+, mature, and memory B cells and an increase in regulatory T cells in vivo up to 3–6 months following BM-MSC infusion: CONCLUSION: Treatment with autologous BM-MSCs is feasible and safely reduces relapses and immunosuppression at 12 months in children with severe steroid-dependent INS. Immunomodulatory studies suggest that repeating MSC infusions at 3–6 months may sustain benefit. TRIAL REGISTRATION: EudraCT 2016-004804-77. FUNDING: AIFA Ricerca Indipendente 2016-02364623.

Angela MastronuzziAngela Mastronuzzi
Angela Mastronuzzi
ABAlessandra Basso
Alessandra Basso
GBGiada Del Baldo
Giada Del Baldo
Andrea CaraiAndrea Carai
Andrea Carai
ASAndrea De Salvo
Andrea De Salvo
PFPaolo Cornaglia Ferraris
Paolo Cornaglia Ferraris
Background: Cancer is very disruptive in adolescence and hospitalizations interfere with this development stage in becoming independent, developing social relationships, and making plans for the future. A major challenge in the care of adolescents with cancer is being able to enhance their quality of life. The aim of this project is to increase our understanding of how adventure therapy influenced quality of life for adolescents with cancer. Methods: Bambino Gesù Children’s Hospital, in collaboration with the Tender to Nave Italia Foundation (TTNI), has been conducting a unique project, located on a beautiful brigantine of the Italian Navy. Adventure therapy is a form of experiential therapy that consists of various types of adventure, in particular outdoor and sailing activities. Ninety teenagers have been the protagonists of this project to date and filled out two questionnaires about quality of life and self-esteem, before and after the sailing experience. Results: The adventure provides the opportunity for the participants to build interpersonal relationships and develop life skills that they can benefit from in the future experiences. All participants report a significant improvement in their quality of life and self-esteem at the end of this experience. Conclusion: This collaborative adventure project is a great way to learn and practice new behaviors, improve interpersonal skills, heal painful emotions, overcome personal obstacles and challenges, and help the teenagers to resume their developmental path after an onco-hematological diagnosis.

29 October 2025 in Journal of Neuro-Oncology
Verified
Journal Article
Open access
PDF file
GBGiada Del Baldo
Giada Del Baldo
VRValentina Di Ruscio
Valentina Di Ruscio
ACANTONELLA CACCHIONE
ANTONELLA CACCHIONE
ASAnnalisa Lo Sasso
Annalisa Lo Sasso
LCLudovica Corvino
Ludovica Corvino
Angela MastronuzziAngela Mastronuzzi
Angela Mastronuzzi
Purpose The long-term neurocognitive impact of craniospinal irradiation (CSI) in young children with medulloblastoma (MB) has driven the development of alternative strategies aimed at improving survival while delaying or avoiding CSI. Methods We retrospectively analyzed a cohort of patients under 5 years of age with MB treated at Bambino Gesù Children’s Hospital between 2007 and 2023 with intensive chemotherapy regimens according to AIEOP recommendation. Clinical, radiological, histopathological, molecular, neurocognitive, and toxicity data were collected. Results Among 42 patients under 5 years, 25 met inclusion criteria (median age 25.3 months, range 5.0–51.3). Histology included classic (52%), desmoplastic/nodular (20%), extensive nodularity (16%), and large cell/anaplastic (12%). SHH was the most common molecular subgroup (52%), followed by Group 3 (32%) and Group 4 (16%). At a median follow-up of 95.7 months, 68% were alive in complete remission. Two- and 5-year overall survival (OS) were 80.0% (95%CI: 58.4–91.1) and 65.9% (95%CI: 42.8–81.4); progression-free survival (PFS) was 68.0% (95%CI: 46.1–82.5) and 63.8% (95%CI: 41.8–79.2). Survival differed by risk group: low-risk patients achieved 100% OS and PFS, standard-risk intermediate, high-risk lowest. All experienced grade 3–4 hematological toxicity; late endocrine effects occurred in four patients, no other long-term toxicities reported. median IQ was stable from diagnosis (885.3) to last follow-up (8392.5.4). Conclusion Our retrospective study of infants MB treated with first-line intensive chemotherapy shows encouraging survival rates. Importantly, neurocognitive function was preserved over time, supporting radiation-sparing strategies, and toxicity was manageable in all cases.

21 October 2025 in Tumori Journal
Verified
Journal Article
Open access
APAndrea Paulis
Andrea Paulis
VMValerio Marri
Valerio Marri
ASAndrea De Salvo
Andrea De Salvo
VRValentina Di Ruscio
Valentina Di Ruscio
SGStefania Gaspari
Stefania Gaspari
GMGiuseppe Maria Milano
Giuseppe Maria Milano
Adolescents and young adults (AYA) with cancer often experience significant psychological distress during hospitalization. Virtual reality (VR) is a non-pharmacological intervention, yet its application in pediatric oncology remains limited. In this study, 35 patients aged 12–21 were assigned to either an experimental group (n=20), which received four VR sessions over two weeks in addition to standard care, or a control group (n=15), which received standard care only. Psychological measures included the Distress Thermometer (DT), State-Trait Anxiety Inventory-Y1 (STAI-Y1), and Hospital Anxiety and Depression Scale (HADS). The experimental group showed significant reductions in distress (DT), state anxiety (STAI-Y1), and depressive symptoms (HADS-D) (all p<.05; Cohen’s d medium to large size). No significant changes were observed in the control group. These findings suggest that VR is a feasible, well-tolerated, and potentially effective tool for reducing psychological distress in AYA oncology patients. Such preliminary results support its integration into multidisciplinary care. Further large-scale studies are needed to confirm its efficacy.

30 September 2026 in Children
Verified
Journal Article
Open access
PDF file
EMElisa Marconi
Elisa Marconi
EMElisa Meldolesi
Elisa Meldolesi
SMSilvia Mariani
Silvia Mariani
MMMarika Mauti
Marika Mauti
Nicola DinapoliNicola Dinapoli
Nicola Dinapoli
SCSilvia Chiesa
Silvia Chiesa
Background: Pediatric radiotherapy is often associated with high levels of psychological distress and vulnerability, affecting both patients and their families. In younger children, sedation is frequently required to ensure safety and adequate immobilization during treatment. The original RADAR Project demonstrated that the Multidimensional Assessment for Pediatric Patients in Radiotherapy (M.A.P.-RT) tool accurately predicts the need for sedation in pediatric patients undergoing radiotherapy. The present study aims to extend the validation of the M.A.P.-RT, including a larger cohort of patients, to confirm the tool’s predictive robustness and to identify clinical and psychosocial factors associated with sedation requirements, and to profile psychosocial and behavioural vulnerability according to age and gender. Methods: Pediatric patients referred for RT were prospectively enrolled and assessed with the M.A.P.-RT schedule during the first multidisciplinary consultation. Two outcomes were analysed: the need for procedural sedation and the level of psychological support required (intensive vs. standard). The questionnaire items, domain scores, and total score were examined to identify the factors most strongly associated with these outcomes. Predictive models were then developed using the domain scores, while the total score was evaluated separately. Model performance was assessed by repeated, fully nested 10 × 10-fold cross-validation (internal validation only), and odds ratios with 95% confidence intervals were calculated to estimate the strength of the associations. Linear regression models with age group (children ≤ 11 years vs. adolescents and young adults ≥ 12 years), gender, and their interaction were then fitted to test demographic predictors of psychological difficulties and behavioural reactions at treatment entry. Results: A total of 268 patients (mean age 9.6 years, SD 5.7; 59.3% male) were included in the analysis. Procedural sedation was required in 22.8% of patients, while 51.1% received intensive psychological support. The M.A.P.-RT showed excellent ability to identify children requiring sedation, with previous collaboration during radiotherapy procedures, age-related discomfort, and higher questionnaire scores emerging as the main predictors. The overall questionnaire score alone also provided high predictive accuracy. In contrast, the tool was less effective in distinguishing patients who required intensive psychological support: it misclassified roughly one patient in three, with a significant bias toward over-classifying patients into the higher-need category. Age group, but not gender, predicted psychosocial vulnerability: compared with adolescents and young adults, children aged ≤11 years showed significantly greater psychological difficulties, parental anxiety, post-diagnosis distress, and externalising coping and patient-management difficulties and more pronounced reactions across all five dimensions of the Children’s Emotional Manifestation Scale (CEMS), included in the M.A.P.-RT, at treatment entry. Conclusions: In this large single-centre cohort, and under internal validation only, the M.A.P.-RT confirmed its value as a reliable tool for predicting the need for procedural sedation in pediatric radiotherapy, while its ability to predict the intensity of psychological support was more limited, indicating that it is better used to prompt psychological assessment than to allocate support; this was probably due to different properties of the two targets. Age was the main profiling variable, identifying younger children as systematically more vulnerable; sex was not associated with any outcome. These findings highlight that integrating structured psychosocial information into patient profiling may facilitate the early identification of individual vulnerabilities and support the delivery of more personalized psychosocial care. They also underscore the potential of multidisciplinary assessment tools to enable the early identification of individual needs and vulnerabilities, supporting the development of personalized supportive interventions to improve the radiotherapy experience of children and their families. Because validation was internal and conducted in a single centre, external validation remains necessary before the schedule is adopted elsewhere.

30 September 2026 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
Matteo AmicucciMatteo Amicucci
Matteo Amicucci
ARAdele Ripà
Adele Ripà
ICItalo Ciaralli
Italo Ciaralli
MMManuela Mampieri
Manuela Mampieri
ASAndrea De Salvo
Andrea De Salvo
MIMaria Antonietta De Ioris
Maria Antonietta De Ioris